Related Experiment Video
Updated: Apr 28, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Genetics of long QT syndrome
David J Tester1, Michael J Ackerman1
1Mayo Clinic, Rochester, Minnesota.
Insights
Long QT syndrome (LQTS) is a genetic heart condition causing delayed repolarization and increased risk of sudden cardiac death. Genetic testing is crucial but requires careful interpretation of genotype-phenotype correlations.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Long QT syndrome (LQTS) is a life-threatening cardiac arrhythmia linked to delayed myocardial repolarization.
- It increases the risk of torsades des pointes (TdP), syncope, seizures, and sudden cardiac death (SCD).
- Three major genes (KCNQ1, KCNH2, SCN5A) cause ~75% of LQTS cases, with minor genes accounting for <5%.
Purpose of the Study:
- To review genotype-phenotype correlations in LQTS.
- To discuss risk stratification based on specific mutations.
- To highlight the importance of careful interpretation of genetic testing results.
Main Methods:
- Review of current literature on LQTS genetics and clinical manifestations.
- Analysis of genotype-phenotype correlations for major and minor LQTS genes.
- Discussion of atypical LQTS and syndromic disorders associated with QT prolongation.
Main Results:
- Major LQTS genotypes show gene-specific triggers, ECG patterns, and therapeutic responses.
- Intragenic and mutation-specific risk stratification is increasingly feasible.
- Atypical LQTS syndromes include ankyrin-B, Anderson-Tawil (ATS), and Timothy syndrome (TS).
Conclusions:
- Genetic testing is recommended for suspected or persistent QT prolongation.
- Understanding genotype-phenotype correlations aids in risk stratification and management.
- Careful interpretation of genetic test results is essential for optimal patient care.
Abstract:
Long QT syndrome (LQTS) is a potentially life-threatening cardiac arrhythmia characterized by delayed myocardial repolarization that produces QT prolongation and increased risk for torsades des pointes (TdP)-triggered syncope, seizures, and sudden cardiac death (SCD) in an otherwise healthy young individual with a structurally normal heart. Currently, there are three major LQTS genes (KCNQ1, KCNH2, and SCN5A) that account for approximately 75% of the disorder. For the major LQTS genotypes, genotype-phenotype correlations have yielded gene-specific arrhythmogenic triggers, electrocardiogram (ECG) patterns, response to therapies, and intragenic and increasingly mutation-specific risk stratification. The 10 minor LQTS-susceptibility genes collectively account for less than 5% of LQTS cases. In addition, three atypical LQTS or multisystem syndromic disorders that have been associated with QT prolongation have been described, including ankyrin-B syndrome, Anderson-Tawil syndrome (ATS), and Timothy syndrome (TS). Genetic testing for LQTS is recommended in patients with either a strong clinical index of suspicion or persistent QT prolongation despite their asymptomatic state. However, genetic test results must be interpreted carefully.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Incomplete Dominance
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

